Barclays analyst Stephanie Davis initiated coverage of OptimizeRx with an Equal Weight rating and $15 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OPRX:
- OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
- OptimizeRx price target raised to $14 from $13 at Lake Street
- OptimizeRx Reports Third Quarter 2023 Financial Results
- OptimizeRx sees FY24 revenue at least $110M, consensus $66.06M
- OptimizeRx sees FY23 revenue $68M-$70M, consensus $60.51M